Revisit a 2018 Canadian liraglutide report, its six-month weight-loss findings, and the unanswered questions about muscle and maintenance.
On May 24, 2018, BioSpectrum Asia published a report on a retrospective study of Saxenda (liraglutide) at six Canadian weight-management clinics. Adults receiving care for overweight or obesity were treated with the medication alongside diet and exercise.
According to the report, the six-month findings included:
The weight-loss figures give the report its relevance: they describe outcomes during clinical care rather than only under randomized-trial conditions. For someone discussing medication-assisted weight management, that is useful context about what was reported in these clinics.
The figures also deserve to stay attached to their setting. This was care involving medication, diet and exercise. The headline number belongs to that combination rather than to a medication used in isolation.
Before applying these results to your own goals, it helps to put the evidence boundaries in one place.
The study design limits interpretation. This was a retrospective study rather than a randomized controlled trial. The accessible coverage does not provide the cohort size or detailed participant characteristics. It also lacks a comparison group and enough methodological detail to assess selection effects or separate the contribution of each part of care.
The average is not an individual forecast. The reported 7.1% describes the cohort at six months. The coverage does not establish how representative these patients were of everyone considering liraglutide. It also did not study gay men specifically or establish treatment differences by sexual orientation.
Weight change is not a body-composition assessment. The report provides no measurements showing how much weight lost was fat versus lean tissue. It also provides no muscle or strength results.
Maintenance remains unanswered for this cohort. The coverage supplies no follow-up beyond six months and no outcomes after treatment stopped.
The health and safety details are incomplete. The report does not quantify the blood-glucose or blood-pressure changes. It also does not provide gastrointestinal-event frequencies or severity, or detailed discontinuation data.
The coverage included a favorable assessment from Novo Nordisk executive Mads Krogsgaard Thomsen. His view that the findings were consistent with clinical-trial benefits was a company executive’s assessment rather than independent expert confirmation.
These boundaries give the finding its proper scale. They support using it as context for a clinical conversation rather than as a complete evaluation of treatment.
For a man over 35, the useful next step is to name the outcome that matters before turning a study average into a target. A lower body weight may be part of that outcome. So might staying physically capable or feeling more comfortable in your clothes.
Those preferences do not need to compete. Looking good and protecting long-term health can sit within the same discussion. The practical task is to make each goal explicit rather than asking a single number to represent all of them.
A useful opening with a qualified clinician is: “I want to discuss weight management, but strength and everyday energy matter to me too.” That states your priorities without assuming that one treatment will deliver every outcome.
From there, ask which outcomes the proposed care is intended to address and how progress would be assessed. The point is not to arrive with a self-designed medical protocol. It is to leave with a clearer understanding of what success would mean in your situation.
If physical capability is part of your goal, keep strength in the weight-management conversation rather than allowing body weight to become the only topic. This is a way to make the discussion match your priorities, not a claim that the Canadian report tested a strength-preservation strategy.
The Canadian participants received liraglutide alongside diet and exercise. That makes everyday habits part of the story rather than background detail to remove from the headline.
For your own appointment, describe how eating and physical activity fit into an ordinary week. Include the parts that feel workable and the parts that do not. This gives the conversation a practical starting point without requiring you to invent calorie targets or training rules from this report.
The evidence here does not support turning the study into a detailed meal plan or exercise prescription. Those decisions belong in individualized care rather than in an article built around a clinic-level average.
A more useful question is: “How would the proposed treatment fit with the routine I can realistically maintain?” That keeps the discussion focused on the whole approach described in the report.
There is also no need to present yourself as a perfect patient before asking about care. An accurate account of your routine is more relevant to the conversation than a polished version built around what you think a clinician expects to hear.
It is reasonable to want a clear answer to “Is this working?” The answer starts with agreeing on what is being assessed.
Ask a clinician how weight-related outcomes and your other priorities would be reviewed. If strength matters to you, say so directly. If the central concern is a health measure, ask what that measure means for the proposed care.
For readers who prefer a broader framework, thinking about progress beyond body weight can help organize those questions. It should not become another set of targets to meet without context.
The aim is a shared definition of progress. A study result can inform that discussion, but your clinical plan needs its own purpose and a clear way to review it.
Obesity Canada’s adult clinical practice guideline provides the broader treatment context. It recommends offering pharmacotherapy alongside health-behaviour changes to eligible adults. It also advises long-term use of effective obesity pharmacotherapy with those changes to maintain weight loss and help avoid regain and regression of health benefits.
The guideline notes that clinical trials consistently show weight regain and regression of health improvements when obesity pharmacotherapy is stopped. That is guidance drawn from the wider evidence base, separate from the Canadian clinic report.
For someone considering treatment, this changes the conversation from a short course with a finish line to a discussion about ongoing care. Eligibility and potential benefits need to be considered alongside adverse effects and longer-term planning with a qualified clinician.
Useful questions include:
These are questions for shared decision-making rather than instructions to begin or continue a particular medication. Obesity Canada’s recommendation does not mean that every person with excess weight should receive the same treatment indefinitely.
For a man trying to support health span, the practical shift is to think beyond the first visible change. Ask how the proposed care fits into the life you want to maintain rather than treating a weight-loss milestone as the whole plan.
You do not need a specifically gay treatment effect for gay context to belong in the conversation. Your reasons for seeking care and your preferences about appearance remain relevant to how you discuss your goals.
There is no single physique that this evidence asks a gay man to pursue. Nor does being over 35 create an obligation to become smaller or more muscular. The appropriate question is what you want help with and what qualified care can reasonably offer.
If appearance is a priority, it can be named without apology. If confidence or intimacy is part of your motivation, it can also be discussed without expecting weight treatment to answer every concern.
Keep those personal aims distinct from medical outcome claims. Wanting to feel attractive is a legitimate preference; it is not a finding from this study. That distinction makes room for an adult conversation about health and appearance without turning either into a judgment about your body.
Use the 2018 result to inform a clinician-led discussion about weight management, while making your priorities for strength and longer-term care explicit rather than adopting the cohort average as a personal target.
Taking weight-management questions into a broader conversation about daily life comes next; GayFitLab covers nutrition and healthy aging alongside relationships and sexual wellbeing for gay men 35+. Its evidence-focused coverage addresses the gay context often missing from general men's health advice, supporting a more informed view of body composition without setting one standard for appearance or masculinity.
Stay connected for research-led guidance on fitness, body composition, skin, grooming, vitality, sexual wellbeing, relationships and healthy aging. Clear ideas for gay men 35+ who want to look good, feel strong and age with confidence.
Build habits and systems that support clear thinking, steady energy and long term capacity throughout a demanding career.
explore the Blog
